Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Blood (2025) 146 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2025-7624

Published: 2025

Journal Articles

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Andrea Rivero, Monica Molina, Laura Julià, Víctor Navarro Garces, Juan Correa, Helena Brillembourg, Eduardo Aguilar-Meseguer, Carmen Rodríguez-Miñón, Isabel Hernández, Amanda Perez, Nuria Martinez-Cibrian, Valentin Ortiz-Maldonado, Nil Albiol, Aina Oliver-Caldes, Julio Delgado Gonzalez, Eva Gine, Pablo Mozas, Armando Lopez-Guillermo, Laura Magnano

Blood (2025) 146 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2025-5386

Published: 2025

Journal Articles

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

Blood (2025) 146 (Supplement 1): 3983.

https://doi.org/10.1182/blood-2025-3983

Published: 2025

Journal Articles

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Blood (2025) 146 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2025-2369

Published: 2025

Journal Articles

A rubric‑based comparison of code red and specialists in managing CAR‑T–Related cytokine release syndrome and icans

Leyre Bento De Miguel, Nuria Martinez-Cibrian, Anabelle Chinea, Carlos Pérez Míguez, Davide Crucitti, Jesús Gómez Fernández, Santiago Bonay, Ignacio Borrajo, Carlos Suárez, Adrian Mosquera

Blood (2025) 146 (Supplement 1): 7856.

https://doi.org/10.1182/blood-2025-7856

Published: 2025

Journal Articles

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Anna Torrent, Mireia Morgades, Susana Barrera, Jordi Ribera, Eulàlia Genescà, José González-Campos, Nuria Martinez-Cibrian, Pau Montesinos, Alberto Hernández-Sánchez, Pere Barba, Edgar Zapico, Ricardo Sanchez, Marta Sitges Arriaga, Clara Maluquer Artigal, Esperanza Such, Carmen Botella, Maria Queipo De Llano, Mónica Cabrero Calvo, Ana Maria Vicent Castelló, Paula Lopez de Ugarriza, Mar Tormo, Bernardo Gonzalez Gonzalez, Irene García-Cadenas, Carlos Rodriguez Medina, Pilar Martínez-Sánchez, Arancha Bermúdez, Ignacio Gómez-Centurión, María Herrero García, Juana Ciudad, María Hermosín-Ramos, Josefina Serrano, Jose Angel Raposo Puglia, Laura Solán Blanco, Verónica Roldán Galiacho, María Almudena De Laiglesia Lorenzo, Lucía Gómez Pérez, María Solé Rodriguez, Mará Sol Casado Calderón, Laura Llorente González, Daniel Barrios Decoud, Ferran Vall-Llovera Calmet, Lorenzo Algarra, María Lourdes Amador Barciela, Raimundo Garcia, Antonia Cladera Serra, Juan Miguel Bergua Burgues, Isabel Granada, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera

Blood (2025) 146 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2025-1564

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Blood (2025) 146 (Supplement 1): 130.

https://doi.org/10.1182/blood-2025-130

Published: 2025

Journal Articles

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Blood (2025) 146 (Supplement 1): 5121.

https://doi.org/10.1182/blood-2025-5121

Published: 2025

Journal Articles

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Blood (2025) 146 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2025-6192

Published: 2025

Journal Articles

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Blood (2025) 145 (23): 2762–2767.

https://doi.org/10.1182/blood.2024026831

Published: 2025

Includes: Supplemental data

Journal Articles

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Blood (2025) 145 (22): 2599–2613.

https://doi.org/10.1182/blood.2024025440

Published: 2025

Includes: Supplemental data

Journal Articles

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 965.

https://doi.org/10.1182/blood-2024-205669

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Blood (2024) 144 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2024-205568

Published: 2024

Journal Articles

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 112.

https://doi.org/10.1182/blood-2024-201946

Published: 2024

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis

Jose M. Sanchez-Pina, Pablo Silva, Lucía López-Corral, Anabelle Chinea, Ana Africa Martin Lopez, Nuria Martinez-Cibrian, Rafael Hernani, Victor Noriega, Silvia Filaferro, Pascual Balsalobre, Maria Calbacho, Antonio Pérez-Martínez, Pere Barba, Mi Kwon

Blood (2024) 144 (Supplement 1): 7220.

https://doi.org/10.1182/blood-2024-207963

Published: 2024

Journal Articles

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Valentin Ortiz-Maldonado, Nuria Martínez-Cibrián, Leticia Alserawan, Sergi Betriu, Ana Triguero, Sandra Blum, Margaux Faes, Marte C. Liefaard, Margot J. Pont, Maike Spoon, Kirsten Van Hoorde, Anna D. D. van Muyden, Julio Delgado, Natalia Tovar

Blood (2024) 144 (Supplement 1): 3452.

https://doi.org/10.1182/blood-2024-207546

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients

Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

A rubric‑based comparison of code red and specialists in managing CAR‑T–Related cytokine release syndrome and icans

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Treatment with Siltuximab for Short Term Complications after Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Retrospective Analysis

Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only